Drug Delivery and Toxicities of Adjuvant Chemotherapy in Resected NCSLC
|2||Active, not recruiting||
Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer
† Study has passed its completion date and status has not been verified in more than two years.